Abstract
Understanding the mechanism of cisplatin (CDDP) action may improve therapeutic strategy for ovarian cancer. Although p53 and FLICE-like inhibitory protein (FLIP) are determinants of CDDP sensitivity in ovarian cancer, the interaction between p53 and FLIP remains poorly understood. Here, using two chemosensitive ovarian cancer cell lines and various molecular and cellular approaches, we show that CDDP induces p53-dependent FLIP ubiquitination and degradation, and apoptosis in vitro. Moreover, we showed that Itch (an E3 ligase) forms a complex with FLIP and p53 upon CDDP treatment. These results suggest that p53 facilitates FLIP down-regulation by CDDP-induced FLIP ubiquitination and proteasomal degradation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Apoptosis / drug effects
-
Apoptosis / physiology
-
Blotting, Western
-
CASP8 and FADD-Like Apoptosis Regulating Protein / genetics
-
CASP8 and FADD-Like Apoptosis Regulating Protein / metabolism*
-
Cisplatin / therapeutic use*
-
Drug Resistance, Neoplasm
-
Female
-
Humans
-
Immunoenzyme Techniques
-
Immunoprecipitation
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / metabolism*
-
Ovarian Neoplasms / pathology
-
Protein Processing, Post-Translational
-
RNA, Messenger / genetics
-
RNA, Messenger / metabolism
-
RNA, Small Interfering / pharmacology
-
Reverse Transcriptase Polymerase Chain Reaction
-
Tumor Cells, Cultured
-
Tumor Suppressor Protein p53 / antagonists & inhibitors
-
Tumor Suppressor Protein p53 / genetics
-
Tumor Suppressor Protein p53 / metabolism*
-
Ubiquitin / metabolism
-
Ubiquitination*
Substances
-
Antineoplastic Agents
-
CASP8 and FADD-Like Apoptosis Regulating Protein
-
RNA, Messenger
-
RNA, Small Interfering
-
TP53 protein, human
-
Tumor Suppressor Protein p53
-
Ubiquitin
-
Cisplatin